Lack of interaction between cimetidine and buspirone

Area of Science:

• Pharmacology
• Clinical Pharmacology
• Drug Interactions

Background:

• Cimetidine is known to interact with benzodiazepines, reducing their clearance.
• Buspirone is a nonbenzodiazepine anxiolytic with a different metabolic pathway.
• Investigating potential interactions between cimetidine and buspirone is crucial for patient safety.

Purpose of the Study:

• To evaluate the pharmacokinetic interaction between buspirone and cimetidine.
• To assess the impact of cimetidine on buspirone and its active metabolite, 1-pyrimidinyl piperazine (1-PP).
• To determine if co-administration affects cognitive or mood assessments.

Main Methods:

• A pharmacokinetic study involving 10 healthy male volunteers.
• Administration of buspirone, cimetidine, and their combination over distinct treatment periods.
• Monitoring of buspirone and 1-PP pharmacokinetics, cimetidine excretion, and performance on cognitive and mood tests.

Main Results:

• No significant differences in buspirone pharmacokinetics were observed between treatments.
• A slight but significant increase (31%) in 1-PP Cmax was noted with co-administration.
• No significant changes in cognitive tests or mood scales were detected.

Conclusions:

• Cimetidine is unlikely to cause clinically significant pharmacokinetic interactions with buspirone at normal therapeutic doses.
• The observed increase in 1-PP Cmax does not appear to translate to meaningful clinical effects.
• Co-administration of buspirone and cimetidine can be considered safe within recommended dosage ranges.